Premium
Homegrown private equity firm ChrysCapital has fully exited its more than seven-year-old investment in a pharmaceutical company with below-average returns. ChrysCapital has sold its balance 1.92% stake in Ipca Laboratories Ltd through open market transactions, regulatory filings show. The PE firm had been offloading shares of Ipca since October 2018. It sold ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
